Supreme Court pauses 5th Circuit abortion-pill ruling, preserving access for now
The Supreme Court blocked a 5th Circuit order that would have cut off mifepristone by mail, keeping access intact as Louisiana’s challenge continues.
The Supreme Court’s latest move in the abortion-pill fight stopped a New Orleans-based appeals court from tightening access to mifepristone, at least for now. By pausing a May 1 ruling from the 5th U.S. Circuit Court of Appeals, the justices preserved telemedicine prescribing and mail delivery of the drug while a Republican-led challenge from Louisiana works its way through the courts.
The brief, unsigned order gave no explanation, leaving both sides without guidance even as the case continues. That silence matters because mifepristone has become one of the central pressure points in the post-Roe legal landscape, where battles over abortion increasingly turn on FDA authority, telehealth rules, pharmacy regulation and the federal government’s power to set drug-access standards.
The 5th Circuit has emerged as a national force in those fights. It hears cases from Texas, Louisiana and Mississippi, and 12 of its 17 judges were appointed by Republican presidents, including six by Donald Trump. The court has issued consequential rulings on abortion, gun rights and religious liberty, and has sometimes moved farther right than the Supreme Court itself on major social issues. Tulane University Law School professor Sally Brown Richardson said the court has been willing to “push the jurisprudential envelope” on those questions.
The abortion-pill dispute is the latest example. In 2016, the Food and Drug Administration expanded access to mifepristone to 10 weeks of pregnancy, allowed some nonphysician providers to prescribe it and reduced in-person visit requirements. In 2021, the agency removed the in-person dispensing requirement altogether. FDA materials say mifepristone, together with misoprostol, is approved to end an intrauterine pregnancy through 10 weeks gestation.
That regulatory history has made the drug a target for opponents of abortion access and a test of how far conservative courts can go in reshaping national policy. The Supreme Court unanimously threw out an earlier challenge to the FDA’s actions in 2024 on standing grounds, without reaching the merits. The latest pause does not settle the underlying fight, but it does show the limits of the 5th Circuit’s reach: a court that has become a preferred venue for conservatives and Republican-led states can still run into the Supreme Court’s tolerance level. For abortion-rights advocates, the order is a temporary reprieve. For opponents, it is a sign that the legal battle over medication abortion is far from over.
Know something we missed? Have a correction or additional information?
Submit a Tip
